295 related articles for article (PubMed ID: 12929936)
1. Prostaglandin E2-mediated anabolic effect of a novel inhibitor of phosphodiesterase 4, XT-611, in the in vitro bone marrow culture.
Miyamoto K; Suzuki H; Yamamoto S; Saitoh Y; Ochiai E; Moritani S; Yokogawa K; Waki Y; Kasugai S; Sawanishi H; Yamagami H
J Bone Miner Res; 2003 Aug; 18(8):1471-7. PubMed ID: 12929936
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E2.
Yamagami H; Nishioka T; Ochiai E; Fukushima K; Nomura M; Kasugai S; Moritani S; Yokogawa K; Miyamoto K
Biochem Pharmacol; 2003 Sep; 66(5):801-7. PubMed ID: 12948861
[TBL] [Abstract][Full Text] [Related]
3. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures.
Minamizaki T; Yoshiko Y; Kozai K; Aubin JE; Maeda N
Bone; 2009 Jun; 44(6):1177-85. PubMed ID: 19233324
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2 stimulates the formation of mineralized bone nodules by a cAMP-independent mechanism in the culture of adult rat calvarial osteoblasts.
Kaneki H; Takasugi I; Fujieda M; Kiriu M; Mizuochi S; Ide H
J Cell Biochem; 1999 Apr; 73(1):36-48. PubMed ID: 10088722
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity.
Weinreb M; Shamir D; Machwate M; Rodan GA; Harada S; Keila S
Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):81-90. PubMed ID: 16890416
[TBL] [Abstract][Full Text] [Related]
6. Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models.
Waki Y; Horita T; Miyamoto K; Ohya K; Kasugai S
Jpn J Pharmacol; 1999 Apr; 79(4):477-83. PubMed ID: 10361888
[TBL] [Abstract][Full Text] [Related]
7. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
8. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
9. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
10. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
[TBL] [Abstract][Full Text] [Related]
12. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts.
Park H; Young Lee S; Lee DS; Yim M
Biochem Biophys Res Commun; 2007 Mar; 354(1):178-83. PubMed ID: 17222389
[TBL] [Abstract][Full Text] [Related]
14. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
15. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
16. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
17. EMD273316 & EMD95833, type 4 phosphodiesterase inhibitors, stimulate fibroblastic-colony formation by bone marrow cells via direct inhibition of PDE4 and the induction of endogenous prostaglandin synthesis.
Scutt A; Beier N; Fittschen C
BMC Pharmacol; 2004 Jun; 4():10. PubMed ID: 15219232
[TBL] [Abstract][Full Text] [Related]
18. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
Eur J Pharmacol; 2007 Mar; 559(2-3):219-26. PubMed ID: 17250824
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Sawanishi H; Suzuki H; Yamamoto S; Waki Y; Kasugai S; Ohya K; Suzuki N; Miyamoto K; Takagi K
J Med Chem; 1997 Sep; 40(20):3248-53. PubMed ID: 9379444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
